PIAGGIO; Eliane

Patent Applications and Registrations

Patent applications and USPTO patent grants for PIAGGIO; Eliane.The latest application filed is for "interleukin-2 variants with modified biological activity".

Company Profile

11.12.19

PIAGGIO; Eliane - Paris FR
Piaggio; Eliane - Paris Cedex 13 FR
Piaggio; Eliane - Paris Cedex FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Interleukin-2 Variants with Modified Biological Activity App 20220193198 - PIAGGIO; Eliane ; et al.	2022-06-23
Immune cells defective for Suv39h1 Grant 11,285,176 - Amigorena , et al. March 29, 2	2022-03-29
Immune Cells Defective For Suv39h1 App 20220040235 - AMIGORENA; Sebastian ; et al.	2022-02-10
Use Of Low Dose Il-2 For Treating Autoimmune-related Or Inflammatory App 20210038691 - Klatzmann; David ; et al.	2021-02-11
Use of low dose IL-2 for treating autoimmune--related or inflammatory disorders Grant 10,765,723 - Klatzmann , et al. Sep	2020-09-08
Immune Cells Defective For Suv39h1 App 20200171090 - AMIGORENA; Sebastian ; et al.	2020-06-04
Inhibitor Of Suv39h1 Histone Methyltransferase For Use In Cancer Combination Therapy App 20200157225 - AMIGORENA; Sebastian ; et al.	2020-05-21
Inhibitor Of Suv39h1 Histone Methyltransferase For Use In Cancer Combination Therapy App 20200147099 - AMIGORENA; Sebastian ; et al.	2020-05-14
Immune cells defective for SUV39H1 Grant 10,576,103 - Amigorena , et al.	2020-03-03
Immune Cells Defective For Suv39h1 App 20190365807 - AMIGORENA; Sebastian ; et al.	2019-12-05
Use Of Low Dose Il-2 For Treating Autoimmune - Related Or Inflammatory Disorders App 20190351023 - Klatzmann; David ; et al.	2019-11-21
Use of low dose IL-2 for treating autoimmune related or inflammatory disorders Grant 10,293,028 - Klatzmann , et al.	2019-05-21
Methods For The Diagnostic Of An Autoimmune Disease App 20190056392 - PIAGGIO; Eliane ; et al.	2019-02-21
Boosting Treg cells for treating Alzheimer disease and related disorders Grant 10,183,061 - Dorothee , et al. Ja	2019-01-22
IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease Grant 10,114,018 - Piaggio , et al. October 30, 2	2018-10-30
Protozoan Variant-specific Surface Proteins (vsp) As Carriers For Oral Drug Delivery App 20180228913 - KLATZMANN; David ; et al.	2018-08-16
Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof Grant 9,801,927 - Klatzmann , et al. October 31, 2	2017-10-31
Use Of Low Dose Il-2 For Treating Autoimmune Related Or Inflammatory Disorders App 20170304402 - Klatzmann; David ; et al.	2017-10-26
Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery Grant 9,757,471 - Klatzmann , et al. September 12, 2	2017-09-12
Method for stimulating T lymphocytes with IL-2 Grant 9,669,071 - Klatzmann , et al. June 6, 2	2017-06-06
Methods For The Diagnostic Of An Autoimmune Disease App 20170045512 - PIAGGIO; Eliane ; et al.	2017-02-16
Boosting Treg Cells For Treating Alzheimer Disease And Related Disorders App 20160287671 - DOROTHEE; Guillaume ; et al.	2016-10-06
Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery Grant 9,457,096 - Klatzmann , et al. October 4, 2	2016-10-04
Protozoan Variant-specific Surface Proteins (vsp) As Carriers For Oral Drug Delivery App 20150157735 - Katzmann; David ; et al.	2015-06-11
Protozoan Variant-specific Surface Proteins (vsp) As Carriers For Oral Drug Delivery App 20140011739 - KLATZMANN; David ; et al.	2014-01-09
Use Of Low Dose Il-2 For Treating Autoimmune - Related Or Inflammatory Disorders App 20140004080 - Klatzmann; David ; et al.	2014-01-02
Pharmaceutical Compositions Comprising A Polypeptide Comprising At Least One Cxxc Motif And Heterologous Antigens And Uses Thereof App 20130095133 - Klatzmann; David ; et al.	2013-04-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.